Should Dividend Investors Buy Bristol Myers Stock?
Before income investors put down their hard-earned money on a stock, they need to ask themselves a simple question: Based on my due diligence, do I have the utmost confidence that this company can pay dividends for many years to come?
If the answer isn't an emphatic yes, it may be better to pass on the stock altogether. The pharmaceutical industry is known for sometimes being quite lucrative. But the challenging side to the industry is that companies often live and die by drug patents. This variability can be detrimental to paying a sustainable dividend to shareholders.
Since going public in 1933 amid the Great Depression, Bristol Myers Squibb (NYSE: BMY) has consistently paid dividends for the last 90 years. The company arguably has the track record to elicit a yes to the above question. But is the stock a buy right now? Let's investigate Bristol Myers' fundamentals and valuation to find an answer.
Source Fool.com
